Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179326
Title: | Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
Author: | Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro de Acosta, Manuel Domislovic, Viktor Suris, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi Di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobatón, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri |
Keywords: | Malaltia de Crohn Malalties inflamatòries intestinals Inflammatory bowel diseases Crohn's disease |
Issue Date: | 29-Jun-2021 |
Publisher: | MDPI AG |
Abstract: | Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm10132914 |
It is part of: | Journal of Clinical Medicine, 2021, vol. 10, num. 13, p. 2914 |
URI: | http://hdl.handle.net/2445/179326 |
Related resource: | https://doi.org/10.3390/jcm10132914 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-10-02914-v3.pdf | 1.16 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License